Phase 2 Castration-resistant Clinical Trials
67 recruitingPhase 2
What is a Phase 2 trial?
Phase 2 trials evaluate whether a treatment works for a specific condition and further assess its safety. These studies typically enroll several hundred participants and provide preliminary data on effectiveness.
Showing 1–20 of 67 trials
Recruiting
Phase 2
SHR-1701 in Combination With Stereotactic Body Radiotherapy in mCRPC
Prostate CancermCRPC (Metastatic Castration-resistant Prostate Cancer)
Fudan University66 enrolled3 locationsNCT07451795
Recruiting
Phase 1Phase 2
Radiation Medication (Radium-223 Dichloride) Versus Radium-223 Dichloride Plus Radiation Enhancing Medication (M3814) Versus Radium-223 Dichloride Plus M3814 Plus Avelumab (a Type of Immunotherapy) for Advanced Prostate Cancer Not Responsive to Hormonal Therapy
Stage IVB Prostate Cancer AJCC v8Metastatic Malignant Neoplasm in the BoneMetastatic Castration-Resistant Prostate Carcinoma+1 more
National Cancer Institute (NCI)90 enrolled32 locationsNCT04071236
Recruiting
Phase 2
Bipolar Androgen Therapy + Carboplatin in mCRPC
Homologous Recombination DeficiencyCastration-resistant Prostate Cancer
St Vincent's Hospital, Sydney30 enrolled1 locationNCT03522064
Recruiting
Phase 2
A Study of Talazoparib With or Without Enzalutamide in People With Prostate Cancer Who Have Previously Received Abiraterone Acetate
Prostate Cancer (Adenocarcinoma)mCRPC (Metastatic Castration-resistant Prostate Cancer)
Prostate Cancer Clinical Trials Consortium126 enrolled2 locationsNCT06844383
Recruiting
Phase 1Phase 2
Open-Label Study of Pocenbrodib Alone and in Combination With Abiraterone Acetate, Olaparib, or 177Lu-PSMA-617
Prostate CancerNeoplasmsNeoplasms by Site+7 more
Pathos AI, Inc.252 enrolled18 locationsNCT06785636
Recruiting
Phase 1Phase 2
A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)
MetastasisCastration-Resistant Prostatic Cancer
Merck Sharp & Dohme LLC360 enrolled75 locationsNCT06863272
Recruiting
Phase 2
Stereotactic Body Radiation Therapy Plus Immediate or Delayed Androgen Receptor Pathway Inhibitor and Androgen Deprivation Therapy or Salvage Radiation Therapy for the Treatment of Prostate Cancer, DIVINE Trial
Biochemically Recurrent Prostate CarcinomaRecurrent Castration-Sensitive Prostate CarcinomaRecurrent Prostate Cancer+1 more
Mayo Clinic532 enrolled3 locationsNCT06378866
Recruiting
Phase 2
Pembrolizumab Plus 177Lu-PSMA-617 in Patients With Castration Resistant Prostate Cancer
Prostate CancerProstate CarcinomaMetastatic Castration-resistant Prostate Cancer+1 more
University of California, San Francisco48 enrolled1 locationNCT05766371
Recruiting
Phase 1Phase 2
Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A)
Prostatic Neoplasms, Castration-Resistant
Merck Sharp & Dohme LLC220 enrolled77 locationsNCT06353386
Recruiting
Phase 2
Study of PF-07248144 in Advanced or Metastatic Solid Tumors
Locally Advanced or Metastatic ER+ HER2- Breast CancerLocally Advanced or Metastatic Castration-resistant Prostate CancerLocally Advanced or Metastatic Non-small Cell Lung Cancer
Pfizer320 enrolled44 locationsNCT04606446
Recruiting
Phase 2
Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors
Endometrial CancerLocally Advanced Malignant Solid NeoplasmMetastatic Malignant Solid Neoplasm+10 more
Rahul Aggarwal89 enrolled3 locationsNCT03682289
Recruiting
Phase 1Phase 2
Green Tea and Quercetin in Combination With Docetaxel Chemotherapy in Castration-resistant Prostate Cancer Patients
Metastatic Castration-resistant Prostate Cancer (mCRPC)
Charles Drew University of Medicine and Science99 enrolled1 locationNCT06615752
Recruiting
Phase 2
Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations
Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Metastatic Breast Carcinoma+28 more
National Cancer Institute (NCI)36 enrolled4 locationsNCT04550494
Recruiting
Phase 1Phase 2
Abemaciclib Before 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate Cancer
Castration-Resistant Prostate CarcinomaStage IV Prostate Cancer AJCC v8Stage IVB Prostate Cancer AJCC v8+2 more
Vadim S Koshkin30 enrolled1 locationNCT05113537
Recruiting
Phase 1Phase 2
Anti-tumour Activity of (177Lu) rhPSMA-10.1 Injection
Prostate CancerMetastatic Castration-resistant Prostate CancerUrogenital Neoplasms+3 more
Blue Earth Therapeutics Ltd82 enrolled23 locationsNCT05413850
Recruiting
Phase 1Phase 2
A Study of MHB048C in Patients With Advanced Solid Tumors
Advanced Malignant Solid TumormCRPC (Metastatic Castration-resistant Prostate Cancer)
Minghui Pharmaceutical (Hangzhou) Ltd200 enrolled1 locationNCT07192120
Recruiting
Phase 1Phase 2
Ruxolitinib and Enzalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer
Castration-Resistant Prostate CarcinomaStage IVB Prostate Cancer AJCC v8Metastatic Prostate Adenocarcinoma
University of Michigan Rogel Cancer Center39 enrolled3 locationsNCT06616155
Recruiting
Phase 1Phase 2
Gedatolisib in Combination With Darolutamide in Metastatic Castration-Resistant Prostate Cancer
Prostate CancermCRPC (Metastatic Castration-resistant Prostate Cancer)Prostatic Neoplasms, Castration-Resistant+3 more
Celcuity Inc54 enrolled13 locationsNCT06190899
Recruiting
Phase 2
Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial
Castration-Resistant Prostate CarcinomaStage IVB Prostate Cancer AJCC v8
Alliance for Clinical Trials in Oncology474 enrolled101 locationsNCT06632977
Recruiting
Phase 2
A Study of JSB462 (Luxdegalutamide) Plus Lutetium (177Lu) Vipivotide Tetraxetan in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)
Prostatic Cancer, Castration-Resistant
Novartis Pharmaceuticals130 enrolled50 locationsNCT07047118